We focused on developing differentiated, innovative oncology medicines.
We are committed to improving patients’ quality of life and extending their life span.
Our vision Our vision
Through the relentless efforts of our scientists in researching and developing our product candidates, we believe we can meet the unmet needs of cancer patients for new and innovative treatments. Our mission is to transform deadly cancer into a chronical and eventually curable disease, so that patients can live better and longer.
Clinical Trials
Study of AN8025 in Patients With Unresectable Advanced or Metastatic Solid Tumors

product:AN8025

Indications:Melanoma, NSCLC, Solid Tumor
Identifier: CTR20254641

View More
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

product:AN9025

Indications:PDAC, CRC, NSCLC, Melanoma, BTC, Solid Tumor
Identifier: NCT07252479

View More
First in Human, Dose Escalation Study of AN4005

product:AN4005

Indications:Solid Tumor
Identifier: NCT04999384

View More